Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia
Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia.
mBio. 2019 Jul 9;10(4):e01339-19. doi: 10.1128/mBio.01339-19.
is a significant threat to global health for which a vaccine and novel treatment options are urgently needed. Glycans expressed by human cells are commonly targeted by pathogens to facilitate interactions with the host, and thus characterization of these interactions can aid identification of bacterial receptors that can be exploited as vaccine and/or drug targets. Using glycan array analysis, we identified 247 specific interactions between and glycans representative of those found on human cells. Interactions included those with mannosylated, fucosylated, and sialylated glycans, glycosaminoglycans (GAGs), and glycans terminating with galactose (Gal), -acetylgalactosamine (GalNAc), and -acetylglucosamine (GlcNAc). By investigating the kinetics of interactions with selected glycans, we demonstrate that whole-cell has a high affinity for mannosylated glycans (dissociation constant [ ], 0.14 to 0.59 μM), which are expressed on the surface of cervical and urethral epithelial cells. Using chromatography coupled with mass spectrometric (MS) analysis, we identified potential mannose-binding proteins in Pretreatment of cells with mannose-specific lectin (concanavalin A) or free mannose competitor (α-methyl-d-mannopyranoside) substantially reduced gonococcal adherence to epithelial cells. This suggests that targets mannosyl glycans to facilitate adherence to host cells and that mannosides or similar compounds have the potential to be used as a novel treatment option for Multidrug-resistant strains of are emerging worldwide, and novel treatment and prevention strategies are needed. Glycans are ubiquitously expressed by all human cells and can be specifically targeted by pathogens to facilitate association with host cells. Here we identify and characterize the host-glycan binding profile (glycointeractome), which revealed numerous interactions, including high-affinity binding to mannosyl glycans. We identify gonococcal potential mannose-binding proteins and show that uses mannosyl glycans expressed on the surface of cervical and urethral epithelia to facilitate adherence. Furthermore, a mannose-binding lectin or a mannoside compound was able to reduce this adherence. By characterizing the glycointeractome of we were able to elucidate a novel mechanism used by this important pathogen to interact with human cells, and this interaction could be exploited to develop novel therapeutics to treat antibiotic-resistant gonorrhea.
是对全球健康的重大威胁,迫切需要疫苗和新型治疗方法。人类细胞表达的糖链通常是病原体靶向的,以促进与宿主的相互作用,因此,对这些相互作用的特征描述可以帮助识别可被用作疫苗和/或药物靶点的细菌受体。我们使用糖链阵列分析,鉴定了 247 种与代表人类细胞上糖链的聚糖之间的特定相互作用。相互作用包括那些与甘露糖基化、岩藻糖化和唾液酸化糖链、糖胺聚糖 (GAG) 以及以半乳糖 (Gal)、N-乙酰半乳糖胺 (GalNAc) 和 N-乙酰葡萄糖胺 (GlcNAc) 结尾的糖链之间的相互作用。通过研究与选定糖链相互作用的动力学,我们证明整个细胞的 对甘露糖基化聚糖具有高亲和力 (解离常数 [ ],0.14 至 0.59 μM),这些聚糖表达在宫颈和尿道上皮细胞的表面。使用与质谱 (MS) 分析相结合的色谱法,我们鉴定了 中潜在的甘露糖结合蛋白。用甘露糖特异性凝集素 (刀豆球蛋白 A) 或游离甘露糖竞争物 (α-甲基-D-吡喃甘露糖苷) 预处理细胞,可显著降低淋病奈瑟菌对上皮细胞的粘附。这表明 以甘露糖基化糖作为靶标来促进与宿主细胞的粘附,并且甘露糖苷或类似化合物有可能被用作淋病的新型治疗选择。对全球范围内出现的多药耐药淋病奈瑟菌菌株,需要新的治疗和预防策略。聚糖普遍存在于所有人类细胞中,并且可以被病原体特异性靶向以促进与宿主细胞的关联。在这里,我们鉴定和描述了 的宿主-聚糖结合谱 (糖互作组),该图谱揭示了许多相互作用,包括与甘露糖基化聚糖的高亲和力结合。我们鉴定了淋病奈瑟菌的潜在甘露糖结合蛋白,并表明 利用宫颈和尿道上皮表面表达的甘露糖基化聚糖来促进粘附。此外,甘露糖结合凝集素或甘露糖苷化合物能够减少这种粘附。通过对 的糖互作组进行特征描述,我们能够阐明这种重要病原体与人类细胞相互作用所使用的新机制,并且可以利用这种相互作用开发新的治疗方法来治疗对抗生素耐药的淋病。